CD8A and neoplasm: While it is challenging to definitively attribute an anti-tumor role to CXCL16-expressing NK cells, they may contribute to the activation of CXCR6+ immune cells, such as invariant NKT cells and intratumoral CD8+ T cells, potentially enhancing their anti-tumor capacity [146,147].